Sanofi to buy immunology biotech Blueprint for US$9.1 billion
Sanofi agreed to buy Blueprint Medicines for at least US$9.1 billion as the French drugmaker expands further in rare immunological ...
Tag: Sanofi
Sanofi to buy US biopharma group Blueprint for up to US$9.5 billion
France’s Sanofi has agreed to buy US-based Blueprint Medicines Corporation for up to US$9.5 billion to boost its position in ...
Sanofi plans 5 billion euro buyback, sees higher profit growth
SANOFI said it will repurchase five billion euros (S$7 billion) of stock and grow profits more quickly this year as ...
Sanofi announces biggest China investment deal amid China-EU trade tensions
China is seeking to strengthen economic ties with individual members of the European UnionSanofi plans to invest around US$1.05 billion ...
Sanofi boosts preparedness with S$800 million Singapore plant
Modulus can also be reconfigured within a few days to transform between technological platforms, a process which traditionally takes months ...
Sanofi enters exclusive talks with CD&R for Opella sale
Sanofi said on Monday (Oct 21) it had entered exclusive talks for the sale of a 50 per cent controlling ...
France seeks job guarantees from Sanofi over Doliprane painkiller production
Doliprane is France’s best-selling drug and news that it could be partially sold to a foreign investor has prompted political ...
Lenders line up more than 10 billion euros for Sanofi health unit buyout
BANKS and other lenders are lining up more than 10 billion euros (S$14.3 billion) of debt to back a buyout ...
Sanofi invests 1 billion euros in French drug manufacturing
Sanofi will invest more than 1 billion euros (S$1.45 billion) at three facilities in France as it ramps up production ...
Sanofi inks US$1.2 billion vaccine licensing deal with Novavax
Sanofi and Novavax signed a licensing agreement that includes commercialising a combined Covid-19 and flu shot. Novavax will receive US$500 million ...
Forbes 40under40 stands as a distinguished platform revered for its commitment to honoring and applauding the remarkable achievements of exceptional individuals who have yet to reach the age of 40. This esteemed initiative serves as a beacon of inspiration, spotlighting trailblazers across various industries and domains, showcasing their innovation, leadership, and impact on a global scale.
© 2024 Forbes 40under40. All Rights Reserved.